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Abstract
Verapamil is a calcium channel blocker and highly effective in the treatment of hypertension, angina pectoris, and
other diseases. However, the drug has a low bioavailability of 20 to 35% due to the first pass effect. The main objective
of this study was to develop hybrid verapamil-dextran nanostructured lipid carriers (HVD-NLCs) in an attempt to increase
verapamil cellular uptake. The formulations were successfully prepared by a high-shear homogenization method and
statistically optimized using 24 full factorial design. The HVD-NLCs formulations were freeze-dried using trehalose as a
cryoprotectant. The results showed that the optimized formula (VER-9) possessed a particle size (PS), polydispersity index
(PDI), and the percentage of entrapment efficiency (%EE) of 192.29 ± 2.98, 0.553 ± 0.075, and 93.26 ± 2.66%, respectively.
The incorporation of dextran sulfate in the formulation had prolonged the release of verapamil (~ 85% in 48 h) in the
simulated gastric fluid (pH 1.2) and simulated intestinal fluid (pH 6.8). The differential scanning calorimetry analysis
showed no chemical interaction between verapamil and the excipients in the formulation. While wide-angle X-ray
scattering studies demonstrated the drug in the amorphous form after the incorporation in the NLCs. The transmission
electron microscopy and scanning electron microscopy images revealed that the nanoparticles had spherical shape. The
cellular uptake study using Caco-2 cell line showed a higher verapamil uptake from HVD-NLCs as compared to
verapamil solution and verapamil-dextran complex. The optimized formulation (VER-9) stored in the refrigerated
condition (5 °C ± 3 °C) was stable for 6 months. In conclusion, the HVD-NLCs were potential carriers for verapamil as
they significantly enhanced the cellular uptake of the drug.
Keywords: Verapamil hydrochloride, Dextran sulfate sodium, Nanostructured lipid carriers, Factorial design, Caco-2 cell
line, Cellular uptake
Background
Verapamil is an L-type calcium channel blocking agent
of phenylalkylamine class and an antagonist of the
α-adrenergic receptor. It is extensively used for the treat-
ment of hypertension, supraventricular tachyarrhythmia,
angina pectoris, and cluster headaches. According to the
biopharmaceutics classification system, verapamil is clas-
sified as class I drug. The drugs under this class are
known to have good absorption via intestinal membrane
(≤ 90%) following oral administration. However, only 20
to 35% of the verapamil oral dose is passed to the blood
circulation due to rapid first pass metabolism through
portal circulation [1]. Therefore, it is important to de-
velop suitable carriers that can enhance verapamil cellu-
lar uptake and possibly improve its bioavailability.
The second generation, lipid-based nanoformulations
such as nanostructured lipid carriers (NLCs) exhibited a
great potential for use in the delivery of therapeutic
agents [2, 3]. The NLCs have higher chemical and phys-
ical stability in comparison to the solid lipid nanoparti-
cles (SLNs), and also they have controlled release
properties. Moreover, NLCs exhibit high loading cap-
acity for drug molecules by forming a fewer ordered
crystal lattice of lipid matrix, that could minimize the
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expulsion of the drug during storage. NLCs are prepared
from lipids, which accelerate the chylomicron formation in-
side the intestines and facilitate the absorption of NLCs that
may increase the bioavailability of drugs [4]. Therefore, the
present study developed hybrid verapamil-dextran nano-
structured lipid carriers (HVD-NLCs) to improve the
cellular uptake of the drug that may lead to increase
its bioavailability.
Most of the lipophilic drugs can easily incorporate into
the NLCs, but it is quite difficult to entrap hydrophilic
drugs like verapamil in a lipid-based nanoformulation.
Thus, in the present study, hybrid NLCs using a coun-
terion dextran sulfate sodium were prepared for enhan-
cing the encapsulation of verapamil and prolonging its
release from the NLCs (Fig. 1). The HVD-NLCs formula-
tions were prepared by the hot and high-shear homo-
genization method and optimized statistically using a 24
full factorial design. Two types of lipids were used in the
study, the solid lipid, Compritol 888 ATO® and the liquid
lipid oleic acid. The prepared HVD-NLCs were charac-
terized for their particle size (PS), zeta potential (ZP),
polydispersity index (PDI), and the percent of drug en-
trapment efficiency (%EE). The optimized HVD-NLCs
were lyophilized using trehalose as a cryoprotectant.
The in vitro release profiles were conducted in alkaline
and acidic environments. The in vitro cellular uptake
study of verapamil from the selected HVD-NLCs was
performed using Caco-2 cell lines. The stability study of
the optimized formulation was conducted for 6 months at
three different conditions (5 °C ± 3 °C, 25 °C ± 2 °C/60%
RH± 5% RH, and 40 °C ± 2 °C/75% RH ± 5% RH).
Methods
Material
Verapamil HCl was purchased from the Wenzhou phar-
maceutical factory (Wenzhou, China). Compritol 888
ATO® (Glycerol dibehenate EP–Glyceryl behenate NF)
was obtained from Gattefosse (Saint-Priest, France). Oleic
acid was procured from R & M chemicals (Essex, UK).
Tween 80® (Polysorbate 80) was purchased from Euro
chemo-pharma Sdn. Bhd. (Penang, Malaysia). Poloxamer
188 (Pluronic® F-68) was procured from Molekula (Dorset,
UK). Trehalose, Sephadex® G-25, and fetal bovine serum
(FBS) were obtained from Sigma-Aldrich (St. Louis, MO,
USA). The Caco-2 cell line was obtained from ATCC
(Virginia, USA). Penicillin-Streptomycin solution 100 X
Fig. 1 Formation of electrostatic complex of water-soluble cationic drug verapamil hydrochloride and counterion polymer dextran sulfate sodium
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was obtained from Biowest (Nuaillé, France). Trypsin
0.25% and Dulbecco’s modified Eagles medium (DMEM)
were procured from GE healthcare life sciences, Hyclone
laboratories (Utah, USA). Passive Lysis Buffer, 5X was pur-
chased from Promega (Wisconsin, USA).
Methods
Preparation of HVD-NLCs
HVD-NLCs were prepared by the hot high-shear homo-
genization method. The lipid phase consisted of Com-
pritol ATO 888® and oleic acid was melted by heating at
85 °C (10 °C above the melting point of solid lipid). The
required amount of verapamil was weighed and dissolved
in the aqueous phase containing a mixture of Tween 80®
and poloxamer 188 at a ratio of 1:1 w/w. The aqueous
phase was heated to the same temperature as lipid phase.
The aqueous phase was poured into the lipid phase and ho-
mogenized using a digital T25 Ultra-Turrax® homogenizer,
IKA® (Staufen, Germany) at 24,000 rpm, 85 °C. Subse-
quently, the dextran sulfate aqueous solution (1:1 ratio to
verapamil) was added slowly into the mixture during the
homogenization process. The prepared HVD-NLCs were
left to cool at room temperature (25 ± 2 °C).
Statistical Optimization of the Formulation Parameters
Using 24 Full Factorial Design and Desirability Function
Approaches
A full factorial design with two levels and four vari-
ables was performed to optimize and evaluate the ef-
fect of formulation independent variables (factors) on
the characteristics (dependent variables or responses)
(Table 1). The true high and low levels for each in-
dependent variable were selected based on the pre-
liminary studies.
The experimental responses obtained from the de-
pendent variables were the results of the individual and
combined effects of the four independent variables. This
two-level experimental design provides sufficient data to
fit the following polynomial equation.
X ¼ β0 þ β1Aþ β2Bþ β3C þ β4Dþ β12AB
þ β13ACþ β14 ADþ β23BCþ β24BD
þ β34CD ð1Þ
Where X is a dependent variable; β0 is an intercept; β1,
β2, β3, and β4 are the coefficients of the independent var-
iables A, B, C, and D respectively. While β12, β13, β14,
β23, β24, and β34 are the respective interactions (i.e., AB,
AC, AD, BC, BD, and CD). The experimental results
were analyzed by a Design-Expert® software version
6.0.10 (Stat-Ease, Inc., Minneapolis, MN, USA) followed
by analysis of variance (ANOVA) to determine the sig-
nificance of factors and their interactions. The statistical
analysis was considered significant when the p values
were < 0.05.
The final formulations were selected on the basis of
the desirability function approach. The desirability func-
tion combines all the responses into one variable to pre-
dict the optimum levels of the studied factors. Therefore,
the desirability was determined to select the optimized
formulations with the lowest particle size (PS) and poly-
dispersity index (PDI) and the highest zeta potential (ZP)
and percent entrapment efficiency (%EE) values. The de-
sirability function converts all responses into a common
scale (0, 1) and combines them by geometric mean for the
optimization of overall metric. The desirability value 1
denotes an acceptable value (most desired value) for
the responses, while desirability value 0 indicates an
unacceptable value.
Measurements of Particle Size, Polydispersity Index, and
Zeta Potential
The PS and PDI of the prepared nanoparticles were mea-
sured using a photon correlation spectrometer (Zetasizer
1000HS/3000HS, Malvern Instrument, Malvern, UK).
The ZP was determined using a zeta potential analyzer
(Zetasizer nano series, Nano Z-red badge, Malvern In-
strument, Malvern, UK). All samples were diluted using
filtered distilled water (0.45 μm Nylon filter) and mea-
surements were done in triplicate manner.
Determination of Percent Entrapment Efficiency
The prepared sample containing free verapamil-dextran
complex and HVD-NLCs were separated by mini-column
centrifugation method using Sephadex® G25. A volume of
1 mL of the sample was placed on the top of the column,
and then centrifuged for 2 min at 2000 rpm. The eluent
that contained HVD-NLCs was collected and lyophilized
using a freeze dryer (Labconco, Free Zone Freeze Dry
Systems, Kansas City, USA).
The lyophilized HVD-NLCs (10 mg) was dissolved
in chloroform and evaporated under nitrogen gas at
40 °C. The dried sample was then dissolved in 1 mL
distilled water, vortexed for 2 min, and centrifuged
Table 1 Description of 24 full factorial design
Factors (independent variables) Low level High level
A: Homogenization time 20.00 min 30.00 min
B: Solid lipid (Compritol 888 ATO®) 270.00 mg 285.00 mg
C: Liquid lipid (oleic acid) 15.00 mg 30.00 mg
D: Surfactants (Poloxamer 188:
Tween 80®, 1:1)
200.00 mg 300.00 mg
Responses (dependent variables) Constraints
PS (nm) Minimize
PDI Minimize
ZP (mV) Maximize
EE (%) Maximize
PS particle size, PDI polydispersity index, ZP zeta potential, EE entrapment efficiency
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(Eppendorf, Germany) at 12,000 rpm for 5 min. The
supernatant was collected and the amount of verapamil
was determined by using a validated high-performance li-
quid chromatography (HPLC) method. The %EE was cal-
culated using the following equation:
%EE ¼ Weight of encapsulated verapamil
Initial weight of verapamil
 100
ð2Þ
The HPLC analysis for quantification of verapamil was
performed using Shimadzu chromatographic system fit-
ted with LC 20AD delivery pump (Kyoto, Japan) and
Phenomenex C18 column (250 × 4.6 mm). The mobile
phase consisted of 20 mM ammonium acetate and
acetonitrile at a ratio of 40:60 (v/v). The pH of the mo-
bile phase was adjusted to pH 6.5 with glacial acetic
acid. The injection volume was 20 μL and detection
wavelength for verapamil was set at 278 nm and the flow
rate was fixed at 1.5 mL/min.
Lyophilization Study
The lyophilization was done at − 40 °C for 24 h using a
Labconco, FreeZone Freeze Dry Systems (Kansas City,
USA). Five types of commonly used sugars, including
mannitol, fructose, sucrose, lactose, and trehalose at
lipid:cryoprotectant ratio of 1:1 were screened, in order
to select a suitable cryoprotectant for the freeze-drying
of the HVD-NLCs. The cryoprotectant which produced
lowest mean PS and PDI of the lyophilized formulation
after reconstitution in distilled water was selected for
further study.
In the next study, the HVD-NLCs formulation was
mixed with the selected cryoprotectant by using two
methods. In the first method, the cryoprotectant was
added after preparation of HVD-NLCs formulation,
and it was named as “after homogenization process.”
While in the second method, the cryoprotectant was
added during the preparation of HVD-NLCs formula-
tion, and it was named as “during homogenization
process.” In the first method, several lipids and cryo-
protectant ratios of 1:1, 1:2, 1:4, 1:6, and 1:8 were pre-
pared and lyophilized. The lyophilized HVD-NLCs
formulations were re-dispersed in the filtered, distilled
water (0.45 μm Nylon filter), and the samples were
evaluated for mean PS, PDI, and %EE. The lipid:cryo-
protectant ratios that produced the lowest PS and PDI
and highest %EE were selected for further studies in the
second mixing method.
In Vitro Release Study
The in vitro release study of verapamil from NLCs was
carried out using a dialysis bag placed in a simulated in-
testinal fluid (pH 6.8) or simulated gastric fluid (pH 1.2)
medium. In this study, 2 mL of HVD-NLCs dispersion
was filled into the dialysis bag (12,000 Da MW cutoff ).
The bag was sealed and then immersed in 150 mL of
preheated release medium. The release study was per-
formed on a hot plate magnetic stirrer set at 100 rpm
stirring speed and 37 °C. At scheduled time intervals of
0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 48, and 72 h, 1 mL
of sample was withdrawn and replaced with the same
volume of fresh medium. The released verapamil con-
centration was determined by the HPLC.
Differential Scanning Calorimetry
The differential scanning calorimetry (DSC) analysis
was carried out using a Perkin-Elmer Pyris 6 DSC
(Perkin-Elmer, Beaconsfield, UK). The samples were
weighed (5–7 mg) into an aluminum pan and sealed
using a standard sample pan crimper press (Perkin-Elmer,
Beaconsfield, UK). DSC curves were recorded at the rate
of 10 °C/min from 0 to 260 °C.
Wide-Angle X-Ray Scattering
The wide-angle X-ray scattering (WAXS) θ/2θ analysis
was performed at room temperature using a PANalytical
X’Pert PRO MRD PW3040 (Almelo, Netherlands) applying
Cu Kα radiation. The samples were run at the temperature
range of 2–60 °C with a scanning rate of 5 °C/min.
Transmission Electron Microscope and Scanning Electron
Microscope
The morphology (i.e., shape and size) of HVD-NLCs was
observed by a transmission electron microscope (TEM)
using (Philips CM12, Eindhoven, Netherlands). A drop
of diluted HVD-NLCs dispersion was placed on a 400
mesh copper grid followed by a negative staining with
2% phosphotungstic acid. The prepared sample was air
dried before the TEM examination.
The morphology of lyophilized HVD-NLCs was ob-
served using a scanning electron microscope (SEM) (Leo
Supra 50 VP field Emission SEM, Oberkochen, Germany).
The lyophilized HVD-NLCs sample was fixed on an
aluminum stub then coated with gold (10 nm thickness)
in a sputtering device at 15 mA for 15 min. The sample
was visualized using an Oxford INCA energy dispersive
x-ray microanalysis system with accelerating voltage of
10 kV.
Cellular Uptake of HVD-NLCs
The in vitro cellular uptake study of verapamil from
HVD-NLCs formulation was investigated using a Caco-2
cell line. The cells were cultured in DMEM growth
media supplemented with 1% penicillin-streptomycin so-
lution and 10% FBS in T-25 tissue culture flask. Then, the
Caco-2 cells were collected and seeded in 48-well plates,
at 60,000 cell density per well with DMEM complete
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media until the cells became confluent and formed a
monolayer on the bottom of the well plate. Several solu-
tions containing the same concentration of verapamil
were prepared by diluting HVD-NLCs, verapamil solution,
and verapamil-dextran complex with DMEM media only.
Verapamil solution and verapamil-dextran complex were
used as controls. Subsequently, the DMEM complete
media of Caco-2 cells monolayer in 48-well plates were
exchanged with different dilutions of HVD-NLCs, ver-
apamil solution, and verapamil-dextran complex and in-
cubated at 37 °C for 6 h. After completing the incubation
period, the HVD-NLCs, verapamil solution, and verapamil-
dextran complex samples were removed from the wells.
The residue of the test samples and dead cells were re-
moved from the monolayers by washing three times with
phosphate-buffered saline (PBS). The cells of monolayer
were lysed by adding passive lysis buffer (200 μL) to each
sample well. Samples were pipetted out and centrifuged at
12,000 rpm for 10 min to extract the verapamil from the
cells. The supernatants were collected and verapamil con-
centration was quantified using the HPLC.
Short-Term Stability Study
The short-term stability study of optimized HVD-
NLCs formulation was performed according to the
international council for harmonization of technical
requirements for pharmaceuticals for human (ICH)
guidelines Q1A (R2). The freshly prepared lyophilized
HVD-NLCs formulation (VER-9) was placed at three
different conditions (5 ± 3 °C, 25 ± 2 °C/60 ± 5% rela-
tive humidity (RH), and 40 ± 2 °C/75 ± 5%RH) for
6 months. The stability of the optimized HVD-NLCs
formulation was examined by measuring PS, PDI, ZP,
and total drug content at 0, 1, 3, and 6 months.
Statistical Analysis
The results were analyzed using one-way analysis of vari-
ance (ANOVA) and followed by a post-hoc Tukey-HSD.
The statistical analysis was performed using IBM® SPSS®
Statistical software (Version 22, NY, USA). All the values
were expressed as the mean and standard deviation
(mean ± SD). The difference was statistically significant
when p < 0.05.
Results and Discussion
Analysis Using 24 Full Factorial Design
The values of the selected independent variables, i.e.,
homogenization time (A), solid lipid concentration (B), li-
quid lipid concentration (C), and surfactant concentration
(D) and the obtained results of the selected responses,
i.e., PS, PDI, ZP, and %EE are shown in Table 2. Each
independent variable and their interactions were evalu-
ated statistically using the ANOVA. The polynomial co-
efficient for each dependent variable was generated by
the Design-Expert® software to quantify the effect of
each independent variable, as shown in Eqs. 3, 4, 5, and 6.
Table 2 Observed responses (mean) in 24 full factorial design for HVD-NLCs
Formula code Factors Responses
A B C D PS (nm) PDI ZP (mV) EE (%)
VER-1 20 270 15 200 207.33 ± 5.68 0.562 ± 0.019 − 37.5 ± 1.17 74.35 ± 4.00
VER-2 30 270 15 200 183.7 ± 5.38 0.629 ± 0.012 − 40.4 ± 1.31 61.01 ± 3.06
VER-3 20 285 15 200 204.5 ± 3.078 0.556 ± 0.049 − 43.8 ± 1.35 77.63 ± 9.36
VER-4 30 285 15 200 189.86 ± 3.76 0.546 ± 0.049 − 43.7 ± 1.31 83.15 ± 6.08
VER-5 20 270 30 200 203.06 ± 4.65 0.409 ± 0.052 − 45.9 ± 2.71 72.33 ± 9.64
VER-6 30 270 30 200 209.5 ± 3.47 0.327 ± 0.037 − 47.5 ± 2.45 72.08 ± 3.95
VER-7 20 285 30 200 201.46 ± 2.36 0.383 ± 0.029 − 49.1 ± 0.953 76.48 ± 17.81
VER-8 30 285 30 200 182.6 ± 6.95 0.382 ± 0.022 − 48.1 ± 1.36 67.11 ± 5.37
VER-9 20 270 15 300 188.4 ± 4.9 0.462 ± 0.043 − 49.1 ± 1.55 97.21 ± 1.615
VER-10 30 270 15 300 170.73 ± 5.53 0.526 ± 0.03 − 45.6 ± 1.17 91.71 ± 9.19
VER-11 20 285 15 300 190.3 ± 8.22 0.451 ± 0.033 − 46.7 ± 1.7 98.81 ± 1.012
VER-12 30 285 15 300 167.96 ± 1.76 0.589 ± 0.101 − 44.5 ± 3.5 84.56 ± 0.162
VER-13 20 270 30 300 173.46 ± 0.75 0.501 ± 0.019 − 46.7 ± 1.13 93.95 ± 4.10
VER-14 30 270 30 300 157.46 ± 3.61 0.429 ± 0.023 − 49.6 ± 2.39 79.86 ± 1.15
VER-15 20 285 30 300 178.36 ± 2.65 0.489 ± 0.048 − 48.1 ± 1.58 95.39 ± 2.16
VER-16 30 285 30 300 162.86 ± 3.35 0.436 ± 0.031 − 49.4 ± 1.08 77.88 ± 2.78
A homogenization time (min), B solid lipid concentration (mg), C liquid lipid concentration (mg), D surfactant concentration (mg), PS particle size, PDI polydispersity
index, ZP zeta potential, EE entrapment efficiency
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The equations only represented the significant factors and
their interactions.
PS ¼ 185:73−7:64A−2:13C−12:03D−2:15AC
þ 2:16BD−3:53CD ð3Þ
PDI ¼ 0:48−0:060C−0:029ACþ 0:039CD ð4Þ
ZP ¼ −45:94−2:06C−1:41Dþ 0:91BD−1:09CD ð5Þ
%EE ¼ 81:40−4:31Aþ 8:45D−2:13AD
þ 1:90BD ð6Þ
where A is the homogenization time (min), B is the solid
lipid concentration (mg), C is the liquid lipid concentra-
tion (mg), and D is the surfactant concentration (mg).
The positive and negative signs before each factor or
interaction factors in the equations are representing ei-
ther a synergistic or an antagonistic effect, respectively.
The response surface plots were generated to observe
the concurrent effect of each factor or factor interactions
on the response parameters.
Effects of Variables on Mean Particle Size
As shown in Eq. 3, factors A, C, and D have antagonistic
effects on particle size (PS). It could be concluded that
increasing the homogenization time (factor A) is simul-
taneously associated with a significant decrease in the
PS of NLCs (p < 0.05). This is probably due to the high
shear force of homogenization that efficiently breaks the
lipid globules into smaller particles. Similarly, increasing
the liquid lipid concentration (C) was found to concur-
rently decrease the PS of the NLCs. This might be attrib-
uted to the ability of oleic acid to decrease the viscosity of
the system as well as the surface tension when combined
with Compritol 888 ATO®, hence produced smaller par-
ticle size of NLCs. The ability of the liquid lipid to de-
crease the viscosity of the system when combined with the
solid lipid was also reported by Jenning et al. when they
prepared a SLN dispersion [5]. The authors observed that
increasing the liquid lipid concentration from 0 to 38% in
the lipid matrix composition would reduce the particle
size. Furthermore, increasing the surfactant concentration
(D) would decrease the PS, because higher amount of sur-
factant present in the system would easily emulsifies the
total lipid contents in the formulation, thus forms smaller
nanoparticles.
Figure 2 shows the significant (p < 0.05) effect of fac-
tors (AC, BD, and CD) interactions on the PS of the
NLC. The positive impact of factor (BD), and the nega-
tive impact of factors (AC and CD interaction) showed a
significant effect on the NLCs particle size. The negative
impact of factor (AC) showed that at longer homo-
genization time and higher liquid lipid concentration
caused a decrease in PS. The interaction between higher
concentrations of solid lipid and surfactant in the NLC for-
mulation (BD interaction) showed a significant positive im-
pact on the particle size, which resulted in larger particle
size. In contrast, the interaction between higher concentra-
tions of the liquid lipid and surfactant (CD interaction)
showed a significant negative impact on the particle size
where smaller size was produced.
Effects of Variables on PDI
As illustrated in Eq. 4, oleic acid is shown to have a
negative impact on the PDI, which means that increasing
oleic acid concentration would lower PDI values and
lead to better distribution of the NLC particles. Similar
effect of oleic acid on NLC was also observed by some
researches [6]. Figure 3 depicted the interaction between
the homogenization time and the liquid lipid concentra-
tion (AC interaction). This interaction showed a signifi-
cant negative effect on the PDI. It means that longer
homogenization time and higher liquid lipid concentra-
tion would lead to a decrease in the PDI values. In
addition, the interaction between the liquid lipid and
surfactant concentrations (CD interaction) showed a
synergistic effect on the PDI values. Thus, simultan-
eously increasing the liquid lipid and surfactant concen-
trations would increase the PDI values and produce less
homogenous HVD-NLCs particles. This might be due to
further increase in the surfactant concentration beyond
the optimized value may cause an accumulation of the
surfactant at the outer surfaces of nanoparticles, which
in turn increases the PDI values. The same pattern was
also observed by Shamma et al., whereby increasing the
surfactant concentration caused an increase in PDI
values of NLCs [7].
Effects of Variables on ZP
The HVD-NLCs formulations had the negative charge
due to the ionization of glyceryl behenate (a fatty acid in
Compritol 888 ATO®), oleic acid, and dextran sulfate
residue. Based on Eq. 5, increasing the amount of oleic
acid had the negative impact on the nanoparticles, and
resulting in increase in the negative charge of the nano-
particles, hence increase ZP of HVD-NLCs. This is pos-
sibly due to excessive ionization of abundant carboxylic
groups in the oleic acid (liquid lipid) [8]. Moreover, gly-
ceryl behenate (solid lipid) also showed a negative effect
on the ZP values, where increasing its concentration in-
creases the ZP of nanoparticles. This is due to higher
ionization of carboxylic in the glyceryl behenate that
lead to higher negative charges at the outer surface of
the nanoparticles.
The BD interaction had a significant positive effect on
the ZP of NLCs, while CD interaction showed a negative
effect (Fig. 4). Increasing the concentration of solid lipid
Khan et al. Nanoscale Research Letters  (2018) 13:323 Page 6 of 16
Fig. 3 Response surface plot depicting the significant (p < 0.05) effect of liquid lipid concentration and interactions between a AC and b CD on
PDI of HVD-NLCs. A homogenization time, C liquid lipid, D surfactant
Fig. 2 Response surface plot depicting the significance (p < 0.05) effect of homogenization time, liquid lipid concentration, surfactant concentration,
and interaction between a AC, b BD, and c CD on the PS of HVD-NLCs. A homogenization time, B solid lipid, C liquid lipid, D surfactant
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and decreasing the concentration of surfactant reduces
the negative charge of the nanoparticles and decreases
the ZP values. Probably, at this stage, lower surfactant
concentration would not be able to ionize the total
amount of solid lipid, that lead to reduce the negative
charges on the nanoparticles surface, thus reduce the ZP
of HVD-NLCs. Furthermore, simultaneously increasing
the concentration of liquid lipid and surfactant (CD
interaction) would significantly increase the ZP value of
HVD-NLCs. This is because more carboxylic acid would
be ionized in the presence of higher surfactant concen-
tration in the formulation.
Effects of Variables on %EE
Equation 6 showed that increasing the homogenization
time would significantly (p < 0.05) decrease the %EE of
the drug. Longer homogenization time could strip or
peel off the drug molecules attached at the outer surface
of the nanoparticles, which resulted in a lower %EE of
the drug in the HVD-NLCs. In contrast, increasing the
surfactant concentration resulted in a higher %EE of the
drug in the HVD-NLCs. This could be due to higher
surfactant concentration would increase its outer surface
coating of NLCs, where part of the drug would be en-
trapped in it. Zhuang et al. and Das et al. suggested that
an adequate concentration of surfactant is essential for
the solubilization of drug molecules inside the lipid lat-
tice and at the outer surface of nanoparticles [9, 10].
As shown in Fig. 5, AD interaction had a significant
(p < 0.05) negative impact, whereby increasing the homo-
genization time and decreasing the amount of surfactant
lowers the %EE of drug in the HVD-NLCs. In contrast, the
interaction between solid lipid and surfactant concentra-
tions (BD interaction) showed a positive effect on %EE of
Fig. 4 Response surface plot depicting the significant (p < 0.05) effect of liquid lipid concentration, surfactant concentration, and interactions
between a BD and b CD on the ZP of HVD-NLCs. B solid lipid, C liquid lipid, D surfactant
Fig. 5 Response surface plot depicting the significant (p < 0.05) effect of homogenization time, liquid lipid concentration, surfactant
concentration, and interactions between a AD and b BD on EE of verapamil in HVD-NLCs. A homogenization time, B solid lipid, D surfactant
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drug. Therefore, increasing the concentration of solid lipid
and surfactant will increase the %EE of the drug in the
HVD-NLCs. This is probably due to the higher surfactant
concentration which would solubilize the excess drug mol-
ecules, and at the same time higher amount of solid lipid
presence in the system has accommodated the excess drug
molecules, hence increase the %EE of the drug in the
HVD-NLCs.
Selection of Optimized HVD-NLCs Using the Desirability
Function
The HVD-NLCs formulations with the code no.VER-9,
VER-11, VER-13, and VER-15 had higher desirability
values of 0.863, 0.852, 0.811, and 0.840, respectively. These
formulations were selected for further study because the
desirability values were closer to 1. The individual and
combined desirability function of all the responses for the
selected formulations is depicted in Fig. 6. The mean PS,
PDI, ZP, and %EE of these formulations were in the range
of 173.46 ± 0.757 to 190.3 ± 8.22, 0.451 ± 0.033 to 0.501 ±
0.019, − 46.73 ± 1.13 to − 49.16 ± 1.55, and 93.95 ± 4.10 to
98.81 ± 1.01, respectively.
Lyophilization Study
Lyophilization is one of the commonly used methods in
the pharmaceutical field to change aqueous formulation
into the dried form to prolong the physical and chemical
stability of the nanoparticle during storage [11, 12]. How-
ever, the lyophilization step produces various stresses to
the sample during the process. So, the need of cryopro-
tectant is essential to avoid the stress condition and pro-
tect the sample. Among the screened cryoprotectants,
trehalose was found to be the most suitable one for pro-
tecting the HVD-NLCs formulations from aggregation
after the lyophilization process. The HVD-NLCs formula-
tions protected with trehalose had the smallest particle
size and lowest PDI (Table 3). Trehalose offers many
advantages over other cryoprotectants including less
chemical interactions and exhibit higher glass transition
temperature which may help to prolong the stability of
nanoparticles. Furthermore, trehalose has been demon-
strated as an efficient cryoprotectant for freeze drying
of Compritol 888 ATO® (Glyceryl behenate) in the
lipid-based nanoparticles [13, 14]. Thus, in the present
study, trehalose was selected as cryoprotectant for the
HVD-NLCs formulations.
Fig. 6 Bar graph displaying the individual and combined desirability of several responses on selected HVD-NLCs formulations. a VER-9, b VER-11,
c VER-13, and d VER-15
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In the next study, different ratios of trehalose were
used in the HVD-NLCs formulations after or during the
homogenization process. Table 4 shows the effects of
different ratios of trehalose added into the formulations
after homogenization on PS, PDI, and %EE.
The mean PS was found in the nano size range, while
PDI was < 1 in all ratios of lipids to trehalose used in the
study. However, the %EE of verapamil was decreased
significantly with increasing the ratio of trehalose to
lipids. The %EE of lipid:trehalose at the ratio of 1:1
Table 3 Screening of different cryoprotectants on the basis of mean PS and PDI
Cryoprotectants (Lipid:cryoprotectant)
ratio
Before lyophilization After lyophilization
PS (nm) PDI PS (nm) PDI
Mannitol 1:1 180.56 ± 3.53 0.575 ± 0.022 9153.57 ± 10,360.71 1 ± 0.00
Fructose 1:1 481.42 ± 41.78 0.941 ± 0.102
Sucrose 1:1 532.98 ± 231.80 1 ± 0.00
Trehalose 1:1 214.92 ± 3.75 0.554 ± 0.039
Lactose 1:1 2153.92 ± 1830.25 1 ± 0.00
PS particle size, PDI polydispersity index
Table 4 Addition of trehalose after homogenization
Formula code (Lipid:trehalose) ratio Testing condition PS (nm) PDI % EE
VER-9 1:0 Before lyophilization 178.34 ± 4.85 0.534 ± 0.0002 97.98 ± 0.96
After lyophilization 372.78 ± 10.81 0.733 ± 0.048 97.61 ± 0.51
1:1 After lyophilization 212.82 ± 3.83 0.544 ± 0.044 67.47 ± 1.61
1:2 329.45 ± 12.10 0.995 ± 0.007 40.68 ± 7.32
1:4 227.93 ± 3.64 0.634 ± 0.812 22.19 ± 3.25
1:6 317.94 ± 65.10 0.812 ± 0.052 9.47 ± 2.93
1:8 260.67 ± 16.35 0.611 ± 0.033 8.37 ± 2.02
VER-11 1:0 Before lyophilization 166.34 ± 3.84 0.465 ± 0.012 99.09 ± 0.29
After lyophilization 1544.18 ± 2064 1 ± 0.00 98.27 ± 0.34
1:1 After lyophilization 171.59 ± 3.69 0.558 ± 0.033 70.28 ± 0.87
1:2 210.97 ± 48.38 0.610 ± 0.041 44.88 ± 3.55
1:4 264.33 ± 13.52 0.748 ± 0.022 23.81 ± 3.17
1:6 231.9 ± 17.64 0.549 ± 0.025 9.06 ± 2.75
1:8 260.33 ± 16.30 0.506 ± 0.078 7.96 ± 2.56
VER-13 1:0 Before lyophilization 165.5 ± 4.34 0.524 ± 0.174 93.90 ± 0.77
After lyophilization 1129.41 ± 657.64 1 ± 0.00 92.77 ± 1.37
1:1 After lyophilization 261.11 ± 13.35 0.608 ± 0.025 71.53 ± 2.85
1:2 188.66 ± 9.19 0.662 ± 0.044 52.81 ± 2.50
1:4 256.45 ± 22.60 1 ± 0.00 25.19 ± 3.90
1:6 272.61 ± 34.13 0.622 ± 0.025 10.64 ± 0.82
1:8 238.02 ± 12.73 0.824 ± 0.030 8.43 ± 3.08
VER-15 1:0 Before lyophilization 174.52 ± 2.97 0.497 ± 0.012 95.87 ± 0.25
After lyophilization 1175.55 ± 1016.11 1 ± 0.00 94.90 ± 1.26
1:1 After lyophilization 232.77 ± 4.55 0.497 ± 0.069 74.95 ± 3.18
1:2 300.91 ± 21.33 0.737 ± 0.036 46.04 ± 9.01
1:4 270.42 ± 19.17 0.659 ± 0.094 27.28 ± 4.32
1:6 289.23 ± 42.33 0.824 ± 0.030 9.39 ± 2.48
1:8 208.55 ± 10.87 0.738 ± 0.022 7.78 ± 3.00
PS particle size, PDI polydispersity index, EE entrapment efficiency
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was significantly higher than the lipid:trehalose ratio of
> 1:1. Increasing the amount of trehalose beyond the
lipid trehalose ratio of 1:1 enhanced the removal of ver-
apamil from the verapamil-dextran sulfate complex.
This is possibly due to the interaction between trehal-
ose and dextran at the outer surface of nanoparticles,
which promotes the displacement of verapamil from
the verapamil-dextran sulfate complex and hence, lo-
wers the %EE of drug in the HVD-NLCs. The inter-
action between trehalose and dextran takes place due
to the formation of sugar-salt complex (trehalose-dex-
tran complex), in that the trehalose (sugar) competes
with cationic verapamil and forms complex with polya-
nionic dextran [15]. Miller et al. measured the viscosity
and glass transition temperature of trehalose with boric
acid and proposed the formation of chemical complex be-
tween trehalose and borate ion (B(OH)4
−) [15]. Therefore,
based on the obtained results, the lipid to trehalose ratios
of 1:1 and 1:2 were selected for the next study of trehalose
addition during homogenization. Table 5 shows that the
results of PS, PDI, and %EE were significantly better when
trehalose were added during homogenization. This could
be due to better mixing of trehalose in the HVD-NLCs
formulation by the homogenization process. It is evident
from the data that there was no significant difference in
the %EE of lipid:trehalose ratios of 1:1 and 1:2. Therefore,
formulation VER-9 and VER-11 at lipid:trehalose ratio of
1:1 was selected for further studies.
In Vitro Release of HVD-NLCs
The release profile of verapamil solution from the se-
lected HVD-NLCs formulations (VER-9 and VER-11) in
SGF and SIF are shown in Fig. 7. The release profile of
verapamil from the VER-9 and VER-11 formulations was
significantly longer than verapamil solution in both SGF
and SIF media. Verapamil was loaded as an ionic com-
plex with dextran sulfate in the HVD-NLCs formulation.
This could be the reason for the sustained release of ver-
apamil from the HVD-NLCS. The formulations released
about ~ 85% of verapamil after 48 h and the drug had a
prolonged release profile up to 72 h. On the other hand,
the verapamil solution released approximately 99% of
verapamil within 4 h. The release profiles of the selected
formulations VER-9 and VER-11 were found almost
similar in SGF and SIF release media. However, the re-
lease of verapamil from VER-9 was found slightly better
as compared to VER-11 in the SGF release medium. The
percentage cumulative release of verapamil at 72 h from
VER-9 (95.91 ± 1.40) was found significantly higher as
compared to VER-11 (90.67 ± 1.16) in the SGF medium.
Therefore, VER-9 was selected as a final formulation and
proceeded for further investigations.
DSC Study
The DSC analysis of verapamil, dextran sulfate, Compri-
tol 888 ATO®, poloxamer 188, trehalose, physical mix-
ture (including Compritol 888 ATO®, poloxamer 188,
Table 5 Addition of trehalose during homogenization (after lyophilization)
Formula code (Lipid:trehalose) ratio PS (nm) PDI % EE
VER-9 1:1 192.29 ± 2.98 0.553 ± 0.075 94.06 ± 2.55
VER-9 1:2 184 ± 3.84 0.694 ± 0.076 93.26 ± 2.66
VER-11 1:1 195.78 ± 4.58 0.568 ± 0.029 94.25 ± 1.57
VER-11 1:2 211.72 ± 3.13 0.760 ± 0.108 92.17 ± 1.67
PS particle size, PDI polydispersity index, EE entrapment efficiency
Fig. 7 Cumulative percentage of verapamil released in a SIF (pH 6.8) and b SGF (pH 1.2) release media for 72 h
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Fig. 8 DSC thermograms of a Compritol 888 ATO, b Polomxamer 188, c verapamil HCl, d dextran sulfate, e trehalose, f verapamil HCl and dextran
sulfate physical mixture, g physical mixture (including Compritol 888 ATO, poloxamer 188, trehalose, verapamil, and dextran sulfate), h placebo, and
i HVD-NLCs formulation (VER-9)
Fig. 9 X-ray patterns of a lyophilized HVD-NLCs formulation (VER-9), b lyophilized blank formulation, c trehalose, d dextran sulfate, e verapamil
HCl, and f Compritol 888 ATO
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trehalose, verapamil, and dextran sulfate), lyophilized
blank formulation (Placebo), and lyophilized HVD-NLCs
formulation (VER-9) are shown in Fig. 8. Verapamil,
dextran sulfate, Compritol 888 ATO®, poloxamer 188, and
trehalose had the melting peak at 144.96 °C, 220.41 °C,
72.46 °C, 50.80 °C, and 100.13 °C, respectively. The ther-
mograms showed that there was no significant shift in the
peaks of physical mixture, lyophilized blank formulation,
and HVD-NLCs formulation (VER-9) when compared to
the individual peak components such as Compritol 888
ATO®, poloxamer 188, trehalose, verapamil, and dextran
sulfate. This indicated the physical compatibility between
the components. The endothermic peak of verapamil at
144.96 °C was no longer seen in the thermogram of
HVD-NLCs formulation (VER-9) (Fig. 8f), which could be
due to verapamil that had changed to amorphous form
when incorporated in the HVD-NLCs matrix [16].
WAXS Study
The WAXS/2θ scans of pure verapamil, dextran sulfate,
bulk Compritol 888 ATO®, trehalose, lyophilized blank
formulation (containing Compritol 888 ATO®, oleic acid,
poloxamer 188, Tween 80®, trehalose, and dextran sul-
fate), and lyophilized HVD-NLCs formulation (VER-9)
are shown in Fig. 9. The diffraction peaks of pure verap-
amil showed specific crystalline nature of the drug at 2θ
scattered angles 14.42°, 16.67°, 17.07°, 18.07°, 18.82°,
20.22°, 23.77°, and 26.27° [17]. However, the WAXS/2θ
scans of HVD-NLCs formulation (VER-9) showed that
the peaks of verapamil diminished indicating a decrease
in the crystallinity of the drug when incorporated in the
lipids of HVD-NLCs. The scan also showed the predom-
inant peaks at 2θ scattered angles 12.47°, 15.17°, 16.87°,
21.07°, and 23.82° which possibly attributed to the crys-
talline structure of Compritol 888 ATO® and trehalose
because none of these peaks showed similarity with
any of the pure verapamil peaks [10]. The results sug-
gested that verapamil was in the amorphous form
when incorporated in the HVD-NLCs formulation.
The Compritol 888 ATO® revealed polymorphic crys-
talline transformation upon heating, whereby it changed
to a more stable form, and showed reduced intensity
peaks at 21.1° and 23.3° in the HVD-NLCs and blank for-
mulations. The WAXS pattern of pure dextran sulfate in-
dicated its amorphous form.
Electron Microscopic Examinations
The particle shape and size of the HVD-NLCs formulation
(VER-9) were examined using the electron microscope.
The liquid preparation of HVD-NLCs formulation (VER-9)
observed under transmission electron microscope (TEM)
showed that the particles had a spherical shape with the
size less than 200 nm (Fig. 10). In contrast, observation
under scanning electron microscope (SEM) revealed that
Fig. 10 TEM image of VER-9 before lyophilization
Fig. 11 SEM images of VER-9 formulation a without trehalose; b with trehalose
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the nanoparticles no longer had a spherical shape following
lyophilization of the formulation without trehalose. How-
ever, the cryoprotective effect of trehalose could be seen
when it was incorporated in the HVD-NLCs formulation
(VER-9). The SEM image indicated that the trehalose
helped to protect the structure of the nanoparticle to such
extent when compared to the lyophilized formulation with-
out the cryoprotectant (Fig. 11).
Cellular Uptake Study of HVD-NLCs
Caco-2 cells have been extensively used to study drugs
intestinal cellular uptake [18]. The Caco-2 cells lines is
spontaneously differentiating to form monolayer which
has significant morphological and biological resemblance
to the intestinal epithelium [19]. Several researchers have
reported the in vitro cytotoxicity studies of Compritol ATO
888® [20], oleic acid [21, 22], Tween 80® [23, 24], and polox-
amer 188 [25]. These substances were used as excipients in
the optimized formulation of HVD-NLCs (VER-9). Based
on their finding, these excipients were safe within the con-
centration used, the cell line type, and cell density that have
been employed in the present study. The concentration of
verapamil in the samples of VER-9, verapamil solution, and
verapamil-dextran complex used in the cellular uptake
study was in the range of 10.03 μg/200 μL to 30.1 μg/
200 μL. It was found that the verapamil cellular uptake was
increased with increasing the verapamil concentration
in the samples. The cellular uptake values of verapamil
from VER-9, verapamil solution, and verapamil-dextran
complex were increased from 6.45 ± 2.62 to 15.92 ±
4.78 μg, 0.89 ± 0.28 to 1.46 ± 0.65 μg, and 0.064 ± 0.019
to 0.118 ± 0.003 μg, respectively (Fig. 12). The verap-
amil cellular uptake from the VER-9 formulation was
10.90- and 134.91-fold higher than the verapamil solu-
tion and verapamil-dextran complex, respectively. The
results indicated that verapamil was passively trans-
ported from HVD-NLCs, verapamil solution, and
verapamil-dextran complex in the caco2-cells. A similar
finding of higher cellular uptake of drugs from a lipid-
based nanoformulation was reported [26].
Caco-2 cells act similarly as cell in animals when stim-
ulated by fatty acid. van Greevenbroek et al. suggested
that the incorporation of long-chain unsaturated fatty
acids (e.g., oleic acid and linoleic acid) into the Caco-2
Fig. 12 In vitro model of Caco-2 cell line showing cellular uptake of
HVD-NLCs (VER-9), verapamil solution, and verapamil-dextran
complex (mean ± SD, n = 3)
Table 6 Stability profile of lyophilized HVD-NLCs (VER-9) in terms of PS, PDI, ZP, and drug content (n = 3) in different storage
conditions
Stability parameters 0 month 1 month 3 month 6 month
Storage condition (5 ± 3 °C)
PS (nm) 193.76 ± 2.10 191 ± 3.17 192.46 ± 4.36 198.43 ± 2.90
PDI 0.542 ± 0.075 0.556 ± 0.052 0.554 ± 0.321 0.525 ± 0.251
ZP (mV) − 48.5 ± 1.31 − 45.3 ± 2.55 − 42 ± 2.65 − 46.11 ± 3.11
Drug content (%EE) 100.03 ± 0.03 99.53 ± 0.72 99.06 ± 1.23 98.46 ± 1.67
Storage condition (25 ± 2 °C/60 ± 5%RH)
PS (nm) 193.76 ± 2.10 962.16 ± 12.36 NM NM
PDI 0.542 ± 0.075 1 NM NM
ZP (mV) − 48.5 ± 1.31 − 46.25 ± 2.36 NM NM
Drug content (%EE) 100.03 ± 0.03 92.69 ± 0.75 87.56 ± 1.26 82.14 ± 1.90
Storage condition (40 ± 2 °C/75 ± 5% RH)
PS (nm) 193.76 ± 2.10 865.12 ± 15.26 NM NM
PDI 0.542 ± 0.075 0.963 ± 0.056 NM NM
ZP (mV) − 48.5 ± 1.31 − 49.47 ± 2.45 NM NM
Drug content (%EE) 100.03 ± 0.03 91.78 ± 0.44 68.24 ± 1.80 65.84 ± 7.88
NM not measurable, PS particle size, PDI polydispersity index, ZP Zeta potential
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cells stimulate the secretion of very low-density lipoproteins
(VLDL) and chylomicrons. In contrast, administration of
saturated fatty acids primarily secretes intermediate- and
low-density lipoproteins (IDL and LDL) [27]. Similar find-
ings of increasing chylomicron secretion by the long-chain
fatty acids were also reported by Caliph et al. in animal
model [28]. In the present investigation, the long-chain fatty
acids (Compritol 888 ATO® and oleic acid) used in the
preparation of the HVD-NLCs may also stimulate the se-
cretion of chylomicron, and hence increase the cellular up-
take of the model drug.
Stability Study
The lyophilized VER-9 formulation was found stable for
6 months at refrigerated condition (5 ± 3 °C) (Table 6).
There were no significant differences in the PS, PDI, ZP,
and %EE after 6 months of stability study at storage
temperature of 5 ± 3 °C. However, the VER-9 formula-
tion was not stable after 1-month storage at the temper-
atures of 25 ± 2 °C/60 ± 5%RH and 40 ± 2 °C/75 ± 5%
RH. The PS and PDI were increased significantly, while the
total drug content decreased significantly. After 1 month of
stability study, the samples were not measurable due to
aggregation and sticky behavior of the nanoparticles.
Conclusion
The lyophilized HVD-NLCs formulation was success-
fully developed and optimized. The lipid carriers had
prolonged the release of verapamil from the HVD-NLCs
formulation. The formulation was in the nano size range
and stable for 6 months at 5 ± 3 °C. The cellular uptake
of verapamil lipid formulation (NLCs) was found higher
than the non-lipid formulations. This suggested that the
NLCs as a lipid carrier for verapamil may play an im-
portant role in improving the absorption of the drug.
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